A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
R-Pharm
Dispatch Biotherapeutics
Context Therapeutics Inc.
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
Novartis
Kumquat Biosciences Inc.
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Seagen Inc.
Pliant Therapeutics, Inc.
Pfizer
Eli Lilly and Company
Pfizer
Bristol-Myers Squibb
The Methodist Hospital Research Institute
Eli Lilly and Company
Eli Lilly and Company
Kivu Bioscience Inc.
Genentech, Inc.
AstraZeneca
MOMA Therapeutics
Astellas Pharma Inc
Kestrel Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Kura Oncology, Inc.
Boehringer Ingelheim
National Cancer Institute (NCI)
Hoffmann-La Roche
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, Irvine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Janssen Research & Development, LLC
OncoC4, Inc.
Revolution Medicines, Inc.
Novartis
Seagen Inc.
Vividion Therapeutics, Inc.
Fate Therapeutics
National Institutes of Health Clinical Center (CC)
Coherus Oncology, Inc.